Clinical Trials
5
Active:0
Completed:2
Trial Phases
2 Phases
Phase 1:2
Phase 2:3
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (5 trials with phase data)• Click on a phase to view related trials
Phase 2
3 (60.0%)Phase 1
2 (40.0%)Tracing the Metabolic Flux of Orally Administered NAD+ Precursors
Phase 1
Recruiting
- Conditions
- Healthy Adults
- Interventions
- Drug: Nicotinamide Mononucleotide (NMN)Drug: Nicotinamide (NAM)
- First Posted Date
- 2025-03-18
- Last Posted Date
- 2025-05-06
- Lead Sponsor
- Metro International Biotech, LLC
- Target Recruit Count
- 32
- Registration Number
- NCT06882096
- Locations
- 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
Phase 1a Single Ascending Dose Study of MIB-725 in Healthy Adults
- First Posted Date
- 2025-02-10
- Last Posted Date
- 2025-02-20
- Lead Sponsor
- Metro International Biotech, LLC
- Target Recruit Count
- 32
- Registration Number
- NCT06815991
- Locations
- 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
Effects of MIB-626 With and Without A High-Intensity Multi-Dimensional Exercise Training Program
Phase 2
Recruiting
- Conditions
- Healthy
- Interventions
- Drug: Investigational Product - MIB 626Drug: PlaceboOther: Usual Physical ActivityOther: Standardized, progressive, high intensity, multidimensional exercise
- First Posted Date
- 2023-05-26
- Last Posted Date
- 2023-11-03
- Lead Sponsor
- Metro International Biotech, LLC
- Target Recruit Count
- 120
- Registration Number
- NCT05878119
- Locations
- 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
Phase 2a MIB-626 vs. Placebo COVID-19
Phase 2
Completed
- Conditions
- Covid19Stage 1 Acute Kidney Injury
- Interventions
- First Posted Date
- 2021-09-09
- Last Posted Date
- 2024-08-27
- Lead Sponsor
- Metro International Biotech, LLC
- Target Recruit Count
- 42
- Registration Number
- NCT05038488
- Locations
- 🇺🇸
The Brigham and Women's Hospital, Boston, Massachusetts, United States
NAD+ Precursor Supplementation in Friedreich's Ataxia
- First Posted Date
- 2021-03-25
- Last Posted Date
- 2023-07-17
- Lead Sponsor
- Metro International Biotech, LLC
- Target Recruit Count
- 7
- Registration Number
- NCT04817111
- Locations
- 🇺🇸
The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
News
No news found